Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients

Wang, HH; Hu, XY; Wang, T; Cui, C; Jiang, J; Dong, K; Chen, S; Jin, CY; Zhao, Q; Du, B; Hu, P

Zhao, Q; Hu, P (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, Beijing, Peoples R China.; Zhao, Q; Hu, P (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China.; Zhao, Q; Hu, P (corresponding author), Key Lab Clin PK & PD Invest Innovat Drugs, Beijing, Peoples R China.; Zhao, Q; Hu, P (corresponding author), NMPA Ke

FRONTIERS IN PHARMACOLOGY, 2021; 12 ():

Abstract

Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索